DiaMedica Therapeutics Inc. (DMAC)

NCM – Цена в реальном времени. Валюта: USD

6.32

-0.13 (-2.02%)

При закрытии: May 12, 2026, 4:00 PM EDT

07.05.2026

DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript

06.05.2026

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today provided a business update and reported financial results for the quarter ended March 31, 2026. Management will host a conference call on Thursday, May 7, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss the Company's business update a.

30.04.2026

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6th. DiaMedica will host a live conference call on Thursday, May 7th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update a.

31.03.2026

DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript

30.03.2026

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS), today provided a business update and reported financial results for the year ended December 31, 2025. Management will host a conference call on Tuesday, March 31, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discus.

30.03.2026

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) will release earnings for its fourth quarter after the closing bell on Monday, March 30.

23.03.2026

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its full-year 2025 financial results will be released after the markets close on Monday, March 30th. DiaMedica will host a live conference call on Tuesday, March 31st at 7:00 AM Central Time to provide a business update and discuss financial resu.

Видео

No Data

There is no data to display

Пресс-релизы

06.05.2026

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

30.03.2026

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS), today provided a business update and reported financial results for the year ended December 31, 2025. Management will host a conference call on Tuesday, March 31, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discus.

05.03.2026

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to evaluate DM199 in a Phase 2 trial in patients with early-onset preeclampsia (PE). This regulatory clearance enables DiaMedica to initiate its Pha.

16.01.2026

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 shares of DiaMedica's common stock to a newly hired non-executive employee whose employment commenced in December 2025. The stock options were a material inducement to the emplo.

DiaMedica Therapeutics Inc. (DMAC)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

Видео

No Data

Пресс-релизы

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

Видео

No Data

Пресс-релизы

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

DiaMedica Therapeutics Inc. (DMAC)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

DiaMedica Therapeutics Inc. (DMAC)

DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

Видео

No Data

Пресс-релизы

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

Видео

No Data

Пресс-релизы

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)